Judge Lets Dana-Farber Advance Cancer Drug IP Suit
By Andrew Karpan (August 16, 2021, 5:57 PM EDT) -- A Massachusetts federal judge has found that the Dana-Farber Cancer Institute made a plausible argument asserting that it is entitled to damages after Bristol-Myers Squibb left the research center's name off immunology patents.
U.S. District Judge Patti B. Saris turned down on Friday efforts by Bristol-Myers Squibb Co. and Ono Pharmaceutical Co. Ltd. to shutter a lawsuit the Boston-based research nonprofit filed in late 2019. The suit accuses the drugmakers of unjustly enriching themselves by licensing a collection of patents Dana-Farber successfully claimed co-ownership of and encouraging other companies not to license the technology from the Dana-Farber Cancer Institute.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!